97. Ulcerative colitis Clinical trials / Disease details
Clinical trials : 2,527 / Drugs : 1,465 - (DrugBank : 259) / Drug target genes : 144 - Drug target pathways : 202
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00207688 (ClinicalTrials.gov) | August 31, 2004 | 13/9/2005 | A Long Term Safety Study of Infliximab (Remicade) in in Ulcerative Colitis Patients | A Multicenter International Study of the Long-term Safety of Infliximab (REMICADE) in Ulcerative Colitis | Ulcerative Colitis | Drug: Infliximab 5 mg/kg;Drug: Infliximab 10 mg/kg;Drug: Placebo | Janssen Research & Development, LLC | Janssen Biologics BV | Completed | N/A | N/A | All | 505 | New Zealand;Switzerland;United Kingdom;Argentina;Australia;Austria;Belgium;Canada;Czechia;Denmark;France;Germany;Israel;Netherlands;United States;Czech Republic |